Gilead’s twice-a-year HIV PrEP drug delivers stunning results in late-stage study

Gilead’s CEO earlier this year said lenacapavir in PrEP is “potentially the most important tool over the past 30 years” to beat back the HIV epidemic.
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks